Neusignal Therapeutics Completes Series B Financing to Advance Alzheimer’s Disease Program NTX-083

Neusignal Therapeutics, a clinical stage neuroscience biotechnology company developing therapeutics for Alzheimer’s disease, has completed a JPY 5.32B Series B financing (approximately USD 36M), including investment from new and existing investors and a grant from AMED’s Drug Discovery Venture Ecosystem Enhancement Project. Proceeds from the Series B will support the Phase 1b clinical trial of NTX-083 in patients with Alzheimer’s disease in the United States later this year. Following trial initiation, Neusignal plans to expand its team as it advances clinical development and prepares for potential strategic partnerships with global pharmaceutical companies. New investors in the round included Angel Bridge and DCI Partners as co-lead investors, as well as Nissay Capital, Red Capital, and Gogin Capital. Existing investors included Fast Track Initiative, Inc. (FTI), Keio Innovation Initiative, Mitsubishi UFJ Capital, SMBC Venture Capital, FFG Venture Business Partners, and Nippon Venture Capital. Makoto Takeuchi, Executive Vice President at FTI, commented: “Since our creation and initial investment in Neusignal Therapeutics, we have continued to support the development of NTX-083, the company’s lead pipeline program. We congratulate the Neusignal team on completing this Series B financing milestone. Following the previous financing, the team has steadily advanced clinical development of NTX-083 and confirmed strong safety and tolerability in healthy volunteers, an important step forward for the program. As patient dosing begins, we look forward to the next stage of development and will continue working with the company and its investors to support the global advancement of NTX-083 as a potential new treatment for Alzheimer’s disease.”   To view the original announcement, visit https://neusignal-tx.com/en/news/20260630-3/

About Neusignal Therapeutics Neusignal Therapeutics is a pioneering biotechnology company based in Tokyo, Japan, focused on the development of innovative therapies for Alzheimer’s disease. Founded as a spin-off from Tohoku University, Neusignal is dedicated to advancing novel drug candidates aimed at slowing the progression of Alzheimer’s, a condition that is rapidly increasing worldwide. With a commitment to addressing the complex challenges of treatment management, high healthcare costs, and patient eligibility, Neusignal strives to bring transformative solutions to those affected by Alzheimer’s. The company is preparing for clinical trials, with plans for both domestic and international development. About Fast Track Initiative: Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 30+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan. Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/